Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris

Circulation

Volumn 105, Issue 11, 2002, Pages 1291-1297

  Grines, Cindy L ^a   Watkins, Matthew W ^a   Helmer, Greg ^a   Penny, William ^a   Brinker, Jeffrey ^a   Marmur, Jonathan D ^a   West, Andrew ^a   Rade, Jeffery J ^a   Marrott, Pran ^a   Hammond, H Kirk ^a   Engler, Robert L ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Angina; Angiogenesis; Collateral circulation; Gene therapy

Indexed keywords

ADENOVIRUS VECTOR; FIBROBLAST GROWTH FACTOR; LIVER ENZYME; PLACEBO;

ADULT; AGED; ANGINA PECTORIS; ANGIOGENESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; EXERCISE TEST; FEMALE; FEVER; FOLLOW UP; GENE TRANSFER; HUMAN; INTRACORONARY INFUSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREADMILL; TREATMENT OUTCOME; VIRAL GENE THERAPY;

ADENOVIRIDAE; ADULT; AGED; ANGINA PECTORIS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRA-ARTERIAL; LIVER; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; TREATMENT OUTCOME;

EID: 0037133624     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc1102.105595     Document Type: Article

References (19)

1. A model to assess interventions to improve collateral blood flow: Continuous administration of agents into the left coronary artery in dogs
2. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart
3. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts
4. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart
5. Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease
6. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
7. Gene therapy for myocardial anglo-genesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia
8. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia
9. Adenovirus vectors for gene delivery
10. Cardiovascular gene therapy
11. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty
12. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury
13. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis
14. Effects of coronary artery bypass surgery and angioplasty on the total ischemic burden: A study of exercise testing and ambulatory ST segment monitoring
15. Asymptomatic cardiac ischemia pilot (ACIP) study, improvement of cardiac ischemia at 1 year after PTCA and CABG
16. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: Outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs cooperative randomized trial
17. Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: Role of the immune response
18. "Sero-switch" adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype
19. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA